TopoTarget A/S  

(Public, CPH:TOPO)   Watch this stock  
Find more results for TOPO
3.60
+0.08 (2.27%)
Apr 23 - Close
CPH real-time data - Disclaimer
Currency in DKK
Range 3.54 - 3.64
52 week 2.10 - 3.80
Open 3.54
Vol / Avg. 2.23M/787,490.00
Mkt cap 515.94M
P/E     -
Div/yield     -
EPS -0.25
Shares 143.32M
Beta     -
Inst. own     -
Apr 24, 2014
Topotarget A/S Annual Shareholder Meeting - 4:00PM GMT+2 - Add to calendar
Mar 27, 2014
Full Year 2013 Topotarget A/S Earnings Conference Call - Webcast
Mar 27, 2014
Full Year 2013 Topotarget A/S Earnings Release
Jan 30, 2014
Q4 2013 Topotarget A/S Earnings Conference Call - Webcast
Jan 30, 2014
Q4 2013 Topotarget A/S Earnings Release
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -1971.65% -419.38%
Operating margin -2145.88% -409.55%
EBITD margin - -387.23%
Return on average assets -11.40% -12.85%
Return on average equity -12.43% -14.15%
Employees 13 -
CDP Score - -

Address

Fruebjergvej 3
KOEBENHAVN, 2100
Denmark
+45-39-178392 (Phone)
+45-39-179492 (Fax)

Website links

Description

Topotarget A/S is a Denmark-based biopharmaceutical company focused on the field of oncology. The Company is engaged in the development of cancer therapies, focusing primarily on the development of its principal drug candidate, Belinostat. Belinostat can be used in combination with full doses of chemotherapy, and is in a pivotal trial within peripheral T-cell lymphoma (PTCL) and phase II in cancer of unknown primary (CUP). It works in partnerships with Spectrum Pharmaceuticals Inc., Multimeric Biotherapeutics Inc. and the National Cancer Institute. As of December 31, 2011, the Company had five wholly owned subsidiaries, namely Topotarget UK Limited, Topotarget Germany AG, Topotarget USA Inc., Topotarget Switzerland S.A. and Topotarget Netherlands B.V. As of December 31, 2011, the Company�s two largest shareholders were HealthCap funds (13.01%) and Avanza bank (6.35%).

Officers and directors

Bo Jesper Hansen M.D., Ph.D. Executive Independent Chairman of the Board
Age: 55
Anders Fink Vadsholt Chief Executive Officer
Age: 43
Lone Dahl Director of Finance
Age: 52
Elisabeth V. Carstensen Ph.D. Director of Pharmaceutical Operations
Age: 43
Anne V. Sillemann Director of Global Regulatory Affairs
Age: 47
Jette Tjoernelund Director of Science
Age: 49
Per Samuelsson Non-Independent Director
Age: 52
Jeffrey H. Buchalter Independent Director
Age: 56
Anker Lundemose M.D., Ph.D. Independent Director
Age: 51
Ingelise Saunders Independent Director
Age: 64